These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37894329)

  • 1. MTH1 Inhibition Alleviates Immune Suppression and Enhances the Efficacy of Anti-PD-L1 Immunotherapy in Experimental Mesothelioma.
    Magkouta SF; Vaitsi PC; Iliopoulou MP; Pappas AG; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.
    Magkouta SF; Pappas AG; Vaitsi PC; Agioutantis PC; Pateras IS; Moschos CA; Iliopoulou MP; Kosti CN; Loutrari HV; Gorgoulis VG; Kalomenidis IT
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32554927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
    Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
    Tada A; Minami T; Kitai H; Higashiguchi Y; Tokuda M; Higashiyama T; Negi Y; Horio D; Nakajima Y; Otsuki T; Mikami K; Takahashi R; Nakamura A; Kitajima K; Ohmuraya M; Kuribayashi K; Kijima T
    Lung Cancer; 2023 Jun; 180():107219. PubMed ID: 37146474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53
    Qiu J; Feng M; Yang G; Cao Z; Liu Y; You L; Zhang T
    Cancer Lett; 2023 Feb; 554():216020. PubMed ID: 36442772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer.
    Zuo B; Li T; Liu X; Wang S; Cheng J; Liu X; Cui W; Shi H; Ling C
    Clin Transl Oncol; 2023 Nov; 25(11):3188-3202. PubMed ID: 37115489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotic MTH1 inhibitor TH1579 induces PD-L1 expression and inflammatory response through the cGAS-STING pathway.
    Shen J; Guillén Mancina E; Chen S; Manolakou T; Gad H; Warpman Berglund U; Sanjiv K; Helleday T
    Oncogenesis; 2024 May; 13(1):17. PubMed ID: 38796460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
    Inaguma S; Ueki A; Lasota J; Komura M; Sheema AN; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Miettinen M; Takahashi S
    J Pathol Clin Res; 2023 May; 9(3):195-207. PubMed ID: 36754859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.
    van Gulijk M; Belderbos B; Dumoulin D; Cornelissen R; Bezemer K; Klaase L; Dammeijer F; Aerts J
    Int J Cancer; 2023 Apr; 152(7):1438-1443. PubMed ID: 36104949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F; Lievense LA; Kaijen-Lambers ME; van Nimwegen M; Bezemer K; Hegmans JP; van Hall T; Hendriks RW; Aerts JG
    Cancer Immunol Res; 2017 Jul; 5(7):535-546. PubMed ID: 28536100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
    Li Y; Amaladas N; O'Mahony M; Manro JR; Inigo I; Li Q; Rasmussen ER; Brahmachary M; Doman TN; Hall G; Kalos M; Novosiadly R; Puig O; Pytowski B; Schaer DA
    PLoS One; 2022; 17(7):e0268244. PubMed ID: 35849586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
    Awad MM; Jones RE; Liu H; Lizotte PH; Ivanova EV; Kulkarni M; Herter-Sprie GS; Liao X; Santos AA; Bittinger MA; Keogh L; Koyama S; Almonte C; English JM; Barlow J; Richards WG; Barbie DA; Bass AJ; Rodig SJ; Hodi FS; Wucherpfennig KW; Jänne PA; Sholl LM; Hammerman PS; Wong KK; Bueno R
    Cancer Immunol Res; 2016 Dec; 4(12):1038-1048. PubMed ID: 27856426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
    Marcq E; Waele J; Audenaerde JV; Lion E; Santermans E; Hens N; Pauwels P; van Meerbeeck JP; Smits ELJ
    Oncotarget; 2017 Oct; 8(52):89722-89735. PubMed ID: 29163783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.